At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
3-(2,4-dimethoxybenzylidene anabaseine) 75 mg or 150 mg orally twice daily for 4 weeksAI-extracted
Key inclusion· 2
- ✓Diagnosis of schizophrenia
- ✓Currently treated with neuroleptic drugs
Key exclusion· 4
- ✕Treatment with clozapine
- ✕Head injury or neurological condition
- ✕Cardiovascular disease
- ✕Substance abuse or dependence, including nicotine
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Trial of the Nicotinic Agonist 3-(2,4 Dimethoxybenzylidene Anabaseine) in Schizophrenia
In Brief
A Phase 2 clinical trial evaluating Placebo, 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg, and 1 other intervention for Schizophrenia. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally administered nicotinic cholinergic agonist, will improve attention and other neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsVA Office of Research and Development
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2004
Enrollment StartJan 2005
Primary CompletionJul 2007
TodayJul 2026
First PostedDec 24, 2004
Enrollment StartJan 1, 2005
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 21.5 years ago
Interventions
Placebodrug
Placebo by mouth twice a day for 4 weeks
3-(2,4 dimethoxybenzylidene anabaseine) 150 mgdrug
3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks
3-(2,4 dimethoxybenzylidene anabaseine) 75 mgdrug
3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks